Back to Search Start Over

The E3 ligase NEURL3 suppresses epithelial-mesenchymal transition and metastasis in nasopharyngeal carcinoma by promoting vimentin degradation.

Authors :
Zhou SQ
Feng P
Ye ML
Huang SY
He SW
Zhu XH
Chen J
Zhang Q
Li YQ
Source :
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Jan 09; Vol. 43 (1), pp. 14. Date of Electronic Publication: 2024 Jan 09.
Publication Year :
2024

Abstract

Background: Metastasis has emerged as the major reason of treatment failure and mortality in patients with nasopharyngeal carcinoma (NPC). Growing evidence links abnormal DNA methylation to the initiation and progression of NPC. However, the precise regulatory mechanism behind these processes remains poorly understood.<br />Methods: Bisulfite pyrosequencing, RT-qPCR, western blot, and immunohistochemistry were used to test the methylation and expression level of NEURL3 and its clinical significance. The biological function of NEURL3 was examined both in vitro and in vivo. Mass spectrometry, co-immunohistochemistry, immunofluorescence staining, and ubiquitin assays were performed to explore the regulatory mechanism of NEURL3.<br />Results: The promoter region of NEURL3, encoding an E3 ubiquitin ligase, was obviously hypermethylated, leading to its downregulated expression in NPC. Clinically, NPC patients with a low NEURL3 expression indicated an unfavorable prognosis and were prone to develop distant metastasis. Overexpression of NEURL3 could suppress the epithelial mesenchymal transition and metastasis of NPC cells in vitro and in vivo. Mechanistically, NEURL3 promoted Vimentin degradation by increasing its K48-linked polyubiquitination at lysine 97. Specifically, the restoration of Vimentin expression could fully reverse the tumor suppressive effect of NEURL3 overexpression in NPC cells.<br />Conclusions: Collectively, our study uncovers a novel mechanism by which NEURL3 inhibits NPC metastasis, thereby providing a promising therapeutic target for NPC treatment.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1756-9966
Volume :
43
Issue :
1
Database :
MEDLINE
Journal :
Journal of experimental & clinical cancer research : CR
Publication Type :
Academic Journal
Accession number :
38191501
Full Text :
https://doi.org/10.1186/s13046-024-02945-9